DHART SPORE Project 3 Phase 2 - A High Content Clinical Trial of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML)

syn51133957

Created By NF Service nf-osi-service

program: NF-OSI
studyName: DHART SPORE Project 3 Phase 2 - A High Content Clinical Trial of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML)
dataStatus: Data Pending
initiative: DHART-SPORE Project 3
studyLeads: Kevin Shannon Mignon Loh
studyStatus: Active
diseaseFocus: Neurofibromatosis type 1
grantEndDate: 1788134400000
institutions: University of California, San Francisco
fundingAgency: NIH-NCI
manifestation: JMML
relatedStudies: syn51133957 syn51298831 syn51133914 syn51133924
clinicalTrialID: clinicaltrials:NCT03190915 clinicaltrials:NCT05849662
studyFileviewId: syn51133961
previousPhaseProject: syn51133946
alternateDataRepository: pride.project:PXD052910
syn51133958
syn51133959
syn51133961
syn51133960

DHART SPORE Project 3 Phase 2 - A High Content Clinical Trial of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML) page is loading…